Nonalcoholic Steatohepatitis Treatment Market| Coherent Market Insights

1
Coherent Marketing Insights

• Market Research Business Consulting Services

• https//www.coherentmarketinsights.com/

• Covid-19 Impact Tracker

2

• NONALCOHOLIC STEATOHEPATITIS TREATMENT SIZE,
  TRENDS, SHARES, INSIGHTS AND FORECAST - 2026
  ANALYSIS
• Nonalcoholic Steatohepatitis Treatment Market, By
  Drug (Cenicriviroc, Elafibranor, Ocaliva, and
  Selonsertib), by Distribution Channel (Hospital
  Pharmacy, Retail Pharmacy, and Online Pharmacy),
  and by Region (North America, Latin America,
  Europe, Asia Pacific, Middle East, and Africa) -
  Size, Share, Outlook, and Opportunity Analysis,
  2018-2026

3

• Nonalcoholic steatohepatitis (NASH) is a form of
  nonalcoholic fatty liver disease (NAFLD) in which
  a person have hepatitis and inflammation of the
  liver, and can cause liver damage. NASH can lead
  to complications, such as cirrhosis and liver
  cancer. Patients with NASH have high chance of
  mortality due to liver-related causes such as
  liver failure.
• Lifestyle modification, including change in diet
  and exercise, is the basic therapy recommended
  for nonalcoholic fatty liver disease. However, in
  some cases lifestyle modification is difficult to
  achieve and to sustain, and therefore required
  other treatments including medicine.
• Currently available drugs for the treatment of
  NAFLD were historically been given for other
  indications. For instance, Orlistat, a gut lipase
  inhibitor, is indicated for decrease in the
  dietary fats absorption. According to the
  National Center for Biotechnology Information
  (NCBI) 2017 study, Orlistat has been approved for
  treatment of obesity and is available over the
  counter in the U.S. for weight loss.
  Orlistat-mediated weight loss is related with
  reduction in hepatic steatosis.

4

• Global Nonalcoholic Steatohepatitis Treatment
  Market Dynamics

5

• Rising incidence of nonalcoholic steatohepatitis
  and strong product pipeline are expected to drive
  the nonalcoholic steatohepatitis treatment market
  revenue
• Nonalcoholic steatohepatitis has become one of
  the most common liver-related health problems.
  The condition has been linked to an unhealthy
  diet and weight gain, but it can also be observed
  in non-obese individuals. Increasing prevalence
  of insulin resistance, and obesity is expected to
  fuel the nonalcoholic steatohepatitis treatment
  market during the forecast period.
• According to an article published in Lancet,
  globally, prevalence of overweight and obesity
  combined has risen by 27.5 for adults between
  1980 and 2013. According to the National Health
  and Nutrition Examination Survey (NHANES) 2014
  data, in U.S. the percentage of obesity is higher
  in women, i.e. 40, than in men, 35.
• Most therapies for NASH are in early- or
  mid-stage development and some are in late-stage
  studies. Multiple companies are focused on the
  development of drugs. In April 2018, AstraZeneca
  has licensed IONIS-AZ6-2.5-L, which has been
  renamed to AZD2693. The newly licensed drug is
  designed to inhibit an undisclosed target to
  treat patients with nonalcoholic steatohepatitis.
  In 2016 Bristol-Myers Squibb acquired rights for
  a NASH program from Osaka, Japan-based Nitto
  Denko Corporation.

6
Nonalcoholic Steatohepatitis Treatment Market -
Regional Insights

• On the basis of region, the global nonalcoholic
  steatohepatitis treatment market is segmented
  into North America, Latin America, Europe, Asia
  Pacific, Middle East, and Africa. North America
  and Europe nonalcoholic steatohepatitis treatment
  market is expected to foresee significant growth
  owing to increasing incidence of obesity and
  fatty liver.
• According to the National Health and Nutrition
  Examination Survey, the proportion of NAFLD among
  chronic liver diseases increased from 47 to 75
  between 1988 and 2008 in the U.S. According to
  the National Institutes of Health, in 2015 nearly
  3 to 12 of adults in the U.S. were suffering
  from NASH. The major reason for this increase was
  an increase in metabolic risk factors. According
  to the Journal of Hepatology, in 2013,
  approximately one-third of adults exhibit a
  pattern of NAFLD in Europe.

7
Global Nonalcoholic Steatohepatitis Treatment
Market Value (US Mn) Y-o-Y Growth ()

8
Nonalcoholic Steatohepatitis Treatment Market -
Competitive Landscape

• Key players operating in the global nonalcoholic
  steatohepatitis treatment market include
  AstraZeneca Plc., Conatus Pharmaceuticals, Enzo
  Biochem, Inc., GENFIT SA, Galmed Pharmaceuticals
  Ltd., Gilead Science, Immuron Ltd., Intercepts
  Pharmaceuticals, Novo Nordisk, Raptor
  Pharmaceutical Corporation, and Tobira
  Therapeutics, Inc.
• Nonalcoholic Steatohepatitis Treatment Market
  Restraints
• Despite the significant burden to the public
  health system, there are no FDA-approved
  specifically tailored drugs for nonalcoholic
  steatohepatitis treatment. Therefore, there is an
  immense need for effective treatment to manage
  the complex pathophysiologic processes of NASH.
  Numerous medications targeting different stages
  and molecular events in the disease process are
  currently in the pipeline, increasing the promise
  of successful treatment of NASH in the future.

9

• Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
• Referance https//www.coherentmarketinsights.com/
  market-insight/nonalcoholic-steatohepatitis-treatm
  ent-market-2279

10
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions. We are headquartered
  in India, having office at global financial
  capital in the U.S. Our client base includes
  players from across all business verticals in
  over 150 countries worldwide.
• What We ProvideCustomized Market Research
  AnalysisIndustry Analysis ServicesBusiness
  Consulting ServicesLong Term Engagement
  ModelCountry Specific Analysis

11
Contact Us

• Mr. Shah
• Coherent Market Insights Pvt. LTD.Coherent
  Market Insights 1001 4th Ave, 3200 Seattle, WA
  98154, U.S.Phone [phone]
• Email sales_at_coherentmarketinsights.com

12
Thank You

• Kindly Follow CMI Social Media Profiles for the
  latest Company Updates.
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/